Spots Global Cancer Trial Database for etelcalcetide
Every month we try and update this database with for etelcalcetide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis | NCT02102204 | Hyperparathyroi... | Etelcalcetide | 18 Years - 110 Years | Amgen | |
| Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) | NCT03299244 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide Cinacalcet | 18 Years - | Amgen | |
| Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis | NCT01785849 | Hyperparathyroi... | Etelcalcetide Placebo | 18 Years - 100 Years | Amgen | |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | NCT03969329 | Secondary Hyper... | Etelcalcetide | 2 Years - 17 Years | Amgen | |
| A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis | NCT03633708 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide | 0 Years - 18 Years | Amgen | |
| A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis | NCT03633708 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide | 0 Years - 18 Years | Amgen | |
| Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis | NCT02102204 | Hyperparathyroi... | Etelcalcetide | 18 Years - 110 Years | Amgen | |
| Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | NCT01254565 | Secondary Hyper... | Etelcalcetide Placebo | 18 Years - | KAI Pharmaceuticals | |
| Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) | NCT03299244 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide Cinacalcet | 18 Years - | Amgen | |
| Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis | NCT02102204 | Hyperparathyroi... | Etelcalcetide | 18 Years - 110 Years | Amgen | |
| Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide | NCT01932970 | Hyperparathyroi... | Etelcalcetide | 18 Years - 100 Years | Amgen | |
| Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis | NCT01785875 | Hyperparathyroi... | Etelcalcetide | 18 Years - 100 Years | Amgen | |
| Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism | NCT01576146 | Secondary Hyper... | Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
| Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide | NCT01932970 | Hyperparathyroi... | Etelcalcetide | 18 Years - 100 Years | Amgen | |
| Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | NCT01134562 | Hyperparathyroi... | Placebo Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
| Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet | NCT01896232 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide Cinacalcet Oral Placebo Intravenous Pla... | 18 Years - 85 Years | Amgen | |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | NCT03969329 | Secondary Hyper... | Etelcalcetide | 2 Years - 17 Years | Amgen | |
| Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis | NCT01788046 | Hyperparathyroi... | Etelcalcetide Placebo | 18 Years - 100 Years | Amgen | |
| Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism | NCT01576146 | Secondary Hyper... | Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | NCT03969329 | Secondary Hyper... | Etelcalcetide | 2 Years - 17 Years | Amgen | |
| Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | NCT01134562 | Hyperparathyroi... | Placebo Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
| A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis | NCT02833857 | Chronic Kidney ... | Etelcalcetide | 2 Years - 17 Years | Amgen | |
| Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis | NCT01788046 | Hyperparathyroi... | Etelcalcetide Placebo | 18 Years - 100 Years | Amgen | |
| Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis | NCT02102204 | Hyperparathyroi... | Etelcalcetide | 18 Years - 110 Years | Amgen | |
| Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis | NCT01788046 | Hyperparathyroi... | Etelcalcetide Placebo | 18 Years - 100 Years | Amgen | |
| Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis | NCT01785849 | Hyperparathyroi... | Etelcalcetide Placebo | 18 Years - 100 Years | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
